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Recurrent Vulvovaginal Infections (RVVI) is common problem associated with women
of reproductive age. The function and deleterious effect of Mannose Binding Lectin 2
(MBL2) common polymorphisms are reported to be associated with various diseases.
However, the role of MBL2 promoter gene polymorphisms and their combined
effect with structural variant along with Serum Mannose Binding Lectin (sMBL)
levels in RVVI has not been investigated. The study included 258 RVVI cases and
203 age matched healthy controls. These were investigated for the distribution of
MBL2 codon 54 and promoter polymorphisms by Amplification Refractory Mutation
System-Polymerase Chain Reaction (ARMS-PCR). sMBL levels were quantified by
Enzyme Linked Immnosorbent Assay (ELISA). The frequency of X allele and its genotypes
was significantly high in cases than controls conferring risk toward RVVI and its types
(p < 0.05). The HXPA (OR; 2.0), LXQB (OR; 1.43) haplotypes were associated with
susceptibility to RVVI cases while haplotype LYQB significantly protected against RVVI
(OR; 0.58), Bacterial Vaginosis (BV) (OR; 0.27) and Mixed Infections (MI) cases (OR;
0.62) with high frequency observed in controls (p < 0.05). Mean sMBL levels were
significantly low in RVVI, BV, Vulvovaginal Candidiasis (VVC), and MI cases compared
to controls (p < 0.05). VVC patient showed significantly low sMBL levels than RVVI and
MI cases (p < 0.05). The mean sMBL levels segregated based on MBL2 genotypes
and haplotypes showed significant difference in different cases groups with controls.
The findings of the present study suggested that MBL2 Y/X polymorphism and low
sMBL levels were associated with susceptibility to RVVI either it is BV, VVC, or MI. Thus
MBL deficiency in women with RVVI may contribute to decreased efficiency in clearing
of pathogens. Hence, specific measures like administration of purified or recombinant
MBL might decrease the incidence of vaginal infections recurrences and more-effective
treatment.
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INTRODUCTION
Vaginal discharge is a common problem of women of
reproductive age. It occurs in 1–14% of all women of reproductive
age throughout the world and its prevalence in India is estimated
to be 30% (Thulkar et al., 2010). It may be caused by a range
of many physiological and pathological conditions including
cervicitis, aerobic vaginitis, atrophic vaginitis, mucoid ectopy
etc. Three common infections associated with Vulvovaginal
Infections (VVI) include Bacterial Vaginosis (BV), followed by
VulvoVaginal Candidiasis (VVC), and Trichomoniasis (Ryan
et al., 1998; Mulu et al., 2015). About 75% of women suffer from
at least one episode of VVC during their reproductive life (Sobel
et al., 1998; Sobel, 2016). Moreover, a subpopulation of women
has emerged with frequent complaints of vaginal infections
referred as recurrent VVI (RVVI) (Powell and Nyirjesy, 2014).
BV and VVC involve disturbance in normal vaginal flora which
is the main cause of both infections. BV is typified by decrease
in hydrogen peroxide producing lactobacilli and overgrowth of
predominantly anaerobic organisms in the vagina while VVC is
caused by excessive growth of Candida species, dimorphic yeast
normally present in the vagina in small numbers and usually
harmless (Sobel, 1988; Forsum et al., 2005). Other Risk factors
for BV and VVC include black race, smoking, use of intrauterine
contraceptive device, sexual activity, recent antibiotic use,
pregnancy, and immunosuppression (Bleicher and Stockdale,
2015; Sobel, 2016). In contrast, Trichomoniasis is a Sexually
transmitted disease. These common infections if left untreated,
can result in increased risk of pelvic inflammatory disease,
infertility, pre-term birth, premature rupture of membranes,
vulvovaginal inflammation, and the risk of spreading other
diseases (Hay et al., 1994; Sobel, 1997; Ralph et al., 1999;
McClelland et al., 2007; Atashili et al., 2008; Toth et al., 2015).
Recognition of all these pathogens by innate host defense
system is mediated by Pathogen recognition receptors (PRRs;
Kumar et al., 2011; Santoni et al., 2015). At present, PRR families
are divided into transmembrane receptors and those that reside
in intracellular compartments. The former include the Toll-like
receptors (TLRs) and C-type lectin receptors (CLRs), and the
latter, the nucleotide-binding oligomerization domain (NOD)
like receptors (NLRs), retinoic acid-inducible gene (RIG) I-like
receptors (RLRs), and AIM2-like receptor (ALR) (Takeuchi and
Akira, 2010; Kumar et al., 2011). Human Mannose-Binding
Lectin (MBL) is a C-type-lectin that binds to a wide variety of
clinical isolates of bacteria, fungi, viruses, and parasites resulting
in immune responses against these pathogens (Van Emmerik
et al., 1994; Neth et al., 2000; Townsend et al., 2001; Neth
et al., 2002; Eisen and Minchinton, 2003; Brouwer et al., 2008;
Kasperkiewicz et al., 2015). MBL is a 32 kDa Protein encoded
by MBL2 mapped to 10q21.1. It is produced mainly in liver and
binds to carbohydrate residues of microbes thereby triggering
complement activation. It is a complex of six sets of homotrimers
of amonomer containing 248 amino acids (Ezekowitz et al., 1988;
Sastry et al., 1989; Taylor et al., 1989; Kurata et al., 1994). This
monomer consists of four domains including a 20-amino acid N-
terminal cysteine-rich domain, a collagen-like domain consisting
of 18–20 tandem repeats of Gly-Xaa-Yaa, an alpha helical
coiled-coil neck region, and a carbohydrate recognition domain.
The neck region initiates the folding and the collagen-like
region zips toward the N terminus, creating trimeric subunits.
Interchain disulfide bonds link trimeric subunits to form and
stabilize higher oligomers of which trimers and tetramers are
probably the predominant form in circulation (Lu et al., 1990;
Wallis and Drickamer, 1999; Teillet et al., 2005).
Single nucleotide polymorphisms (SNPs) present in promoter
and coding region of MBL2 were documented to affect serum
MBL (sMBL) levels. Three SNPs in exon 1 at codon 52
(rs5030737), 54 (rs1800450), and 57 (rs1800451), lead to the
production of non-functional monomers that further interfere
with the formation of higher MBL oligomers, affecting functional
activity of the protein as well as its circulating levels (Sumiya et al.,
1991; Lipscombe et al., 1992; Madsen et al., 1994; Terai et al.,
2003; Larsen et al., 2004). In addition, three other polymorphisms
in the promoter region of the MBL2, L/H (rs11003125), Y/X
(rs7096206), and P/Q (rs7095891) are functionally characterized
to alter the transcriptional levels significantly contributing the
large variations in the promoter activity of MBL2. These findings
elucidate the biological significance of these variations with
respect to gene expression and hence the sMBL levels (Naito et al.,
1999; Jüliger et al., 2000). Also, MBL infusion to MBL deficient
cases was reported to produce satisfactory results with no adverse
consequences (Valdimarsson et al., 1998; Garred et al., 2002).
A plethora of literature is available regarding the association
of MBL gene variations with various diseases including Filariasis,
Malaria, Tuberculosis, Trypanosomiasis, HIV infection, Systemic
Lupus Erythematosus, Rheumatoid Arthritis (Meyrowitsch et al.,
2010; Martiny et al., 2011; Singla et al., 2012; Weitzel et al.,
2012; Li et al., 2013; Panda et al., 2013; Chen et al., 2014;
Jha et al., 2014; Das and Panda, 2015). Limited reports in
various populations have documented the contradicting role of
codon 54 polymorphism in RVVI. Some studies have found an
association of codon 54 polymorphism with increased risk of
VVC (Babula et al., 2003; Liu et al., 2006; Donders et al., 2008;
Wojitani et al., 2012). A single study has reported an association
of codon 54 polymorphism with both VVC and BV. While,
in the same study codon 57 polymorphism was found to be
infrequent and not associated with disease condition (Giraldo
et al., 2007). Also two studies have demonstrated a lack of
association between functional polymorphisms in the first exon
of MBL2 and various RVVI (De Seta et al., 2007; Milanese et al.,
2008). The above difference in association can be attributed to
genetic heterogeneity between different ethnicities and thus need
to be evaluated in different populations.
No studies to date have investigated the role of MBL2
promoter gene polymorphisms and their combined effect with
structural variants along with sMBL levels in RVVI and its types
making the present study first approach toward it.
MATERIALS AND METHODS
Subjects
The present study enrolled 258 cases (mean age ± S.E.M,
29.33 ± 0.51 years) with symptoms including pruitis, burning,
itching, soreness, pelvic pain, vaginal fishy smell, discharge,
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and clinically diagnosed as RVVI cases (at least four clinical
episodes of VVI in the preceding 12 months) by the
gynecologist. These cases were recruited from Department of
Gynaecology and Obstetrics, Bebe Nanki Mother and Child Care
Centre, Government Medical College, Amritsar (Punjab). The
subjects with immunodeficiencies, using immunosuppressive
medications or chemotherapy were excluded from the study. The
control group consisted of 203 (mean age ± S.E.M, 29.33 ±
0.57 years) age-matched healthy women without any recurrent
vaginal infection complaints. The study and its protocols were
approved by the Institutional Human Ethics Committee of Guru
Nanak Dev University, Amritsar (Punjab), India. Samples were
collected after obtaining written consent of the cases and healthy
controls. Details of vaginal sample collection and the diagnosis
of vaginal Candida species, BV, and Trichomoniasis in this study
population have been reported previously (Kalia et al., 2015).
Vaginal samples from RVVI cases (N = 200) were previously
processed for diagnostic test based on European (IUSTI/WHO)
guidelines on the management of vaginal discharge (Sherrard
et al., 2011) which categorized these 200 cases into three main
groups of RVVI i.e., BV (N = 97), VVC (N = 62), and Mixed
Infections (MI; N = 41; Kalia et al., 2015). Majority of the
subjects (≈98%) had Premenopausal status. Very low history of
spontaneous abortions was found in cases (4.3%) and controls
(3.4%). Only 10.46% of cases were taking Oral Contraceptives
Pills (OCPs) and on Intrauterine Devices (IUDs).
Blood Samples Collection and Processing
Blood samples were collected from the cases and healthy subjects.
These samples were then subjected to DNA and serum isolation.
Genomic DNA was isolated from peripheral blood mononuclear
cells (PBMCs) using inorganic method (Miller et al., 1988). In
brief, PBMCs were first lysed and digested, cellular proteins were
then precipitated with ammonium acetate, and the DNA was
precipitated with absolute ethanol. DNA samples were quantified
by measuring optical density (OD) using spectrophotometer
(Eppendorf, India) and yield gel electrophoresis. DNA samples
with concentration above 50 ng/ml, OD > 1.5 and 260/280 ratio
of 1.8 were used for genotype analysis. For serum isolation, blood
samples were incubated at 37◦C and centrifuged at 2000 rpm for
30 min. Isolated DNA and serum samples were stored at −80◦C
pending further use.
Genotyping of MBL2 SNPs
The three SNPs in promoters region i.e., rs11003125 (L/H),
rs7096206 (Y/X), rs7095891 (P/Q), and one SNP rs1800450
(Gly54Asp) present in the first exon of theMBL2 were genotyped
using ARMS-PCR (amplification refractory mutation system-
PCR). PCR was performed in 20 µl reaction volumes containing
50 ng of template DNA, 1X taq buffer containing 1.5 mMMgCl2,
0.025 mM of deoxynucleotide triphosphate, and 0.3 U/ml of
Taq DNA polymerase (GeNei, Bangalore). Concentrations of
specific primers included in each reaction are given in Table 1.
All PCRs were initiated by a 10-min denaturation step at 95◦C
and completed by a 5-min extension step at 72◦C. The PCR
involves 35 cycles of 30 s at 94◦C, 30 s at 55◦C (62◦C for codon
54), and 45 s at 72◦C carried out in a thermocycler (Applied
Biosystems, Life Technologies, USA). The PCR products were
loaded on 1.5% agarose gel (Himedia, India) stained with
ethidium bromide (SRL, India). Gel electrophoresis was carried
out at 100 V and visualized using gel documentation system
(Alpha imagner, USA). The genotypes were ascertained by the
pattern of bands obtained from PCR products. These genotypes
were also confirmed by direct sequence analysis.
MBL Quantification
The sMBL levels were quantified by enzyme linked
immnosorbent assay (ELISA) kit (Ray Biotech, USA) according
to manufacturer’s instructions. Briefly, 100 µl of pre-diluted
sample was added tomicrotitre plate pre-coated with anti-human
MBL antibody and incubated for 2.5 h at room temperature,
after washing with 1X wash buffer, biotinylated anti-human
MBL antibody was added and the plate was incubated at room
temperature for 1 h. Following incubation, unbound biotin
conjugated anti-human antibody was removed by washing with
1X wash buffer and 100 µl streptavidin-HRP was added to
all wells followed by incubation at room temperature for 45
min. After 3–4 washings, TMB substrate was added and color
develops in proportion to the amount of MBL bound. The stop
solution changes the color from blue to yellow; the intensity of
the color was measured at 450 nm.
Statistical Analysis
CatS power calculator (http://www.sph.umich.edu) was used to
calculate the sample size to achieve a power of 99% taking
assumptions of 30% prevalence of vaginal discharge in India and
odds ratio of 1.5 (p = 0.05). The demographic characteristics
of cases and controls were recorded as explanatory variables
and compared by Student’s t-test. sMBL levels (mean ± S.E.M)
within group were compared by one-way ANOVA followed by
Tukey’s multiple comparison post-test. Comparison of genotypic
sMBL levels of cases with respective controls was done by
Student’s t-test. These statistical analyses were carried out by the
SPSS statistical package (Version 16.0). Allelic and Genotypic
frequencies of SNPs of MBL2 were calculated by a simple
allele/genotype counting method. Hardy-Weinberg equilibrium
and inheritance models were determined using SNPStats (Solé
et al., 2006). SNPStats association analysis is based on binary
logistic regression according to the response variable [in this case,
response is status (N = 461)]. Akaike’s Information Criterion
(AIC) and Bayesian Information Criterion (BIC) provided by
SNPStats were used to select the best inheritance model for
each specific polymorphism, with the preferred model being the
one with the lowest AIC/BIC-value. Linkage disequilibrium (LD)
analysis was performed with Haploview v 4.2. Allelic distribution
in cases and controls was compared by odds ratio statistics
using medcal software (https://www.medcalc.org/). The alleles
and corresponding homozygous genotypes with major frequency
in the control group have been selected as reference (OR =
1). Haplotypes were constructed from genotype data by PHASE
software version 2.1.1 (Stephens et al., 2001). p ≤ 0.05 were
considered significant.
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TABLE 1 | Oligonucleotide primers used for MBL2 genotyping by ARMS-PCR.
MBL2 SNP Primer type Sequence Primer conc. used (p mol/µl) Product size (bp)
rs11003125 H specific forward primer 5′-GCTTACCCAGGCAAGCCTGTG-3′ 0.1 316
L specific forward primer 5′-GCTTACCCAGGCAAGCCTGTC-3′ 0.1
Reverse common primer 5′-AACAAATGGGACCGTGCATTGC-3′ 0.05
rs7096206 Forward common primer 5′-CCTGCCAGAAAGTAGAGAGG-3′ 0.15 440
Y specific reverse primer 5′-CTGGAAGACTATAAACATGCTTTCC-3′ 0.15
X specific reverse primer 5′-GGAAGACTATAAACATGCTTTCG-3′ 0.15
rs7095891 P specific forward primer 5′-CAGATTGTAGGACAGAGGGCATGCTC-3′ 0.05 332
Q specific forward primer 5′-TTGTAGGACAGAGGGCATGCTT-3′ 0.1
Reverse common primer 5′-CCAGGCAGTTTCCTCTGGAAGG-3′ 0.05
rs1800450 Forward common primer 5′-CTGCACCCAGATTGTAGGACAGAG-3′ 0.1 278
A specific reverse primer 5′-CCCCCTTTTCTCCCTTGGTGC-3′ 0.1
B specific reverse primer 5′-CCCCCTTTTCTCCCTTGGTGT-3′ 0.1
The nucleotides defining the polymorphisms are underlined.
RESULTS
MBL2 Variants in RVVI Cases and Controls
Frequency of X allele was found to be significantly high in RVVI
cases as compared to controls indicating the increased risk of
RVVI (p < 0.0001; OR = 1.8; 95% CI = 1.36–2.37; Table 2).
However, no difference in allelic frequencies of L/H, P/Q, and
codon 54 polymorphism of MBL2 was observed between RVVI
cases and controls.
For the promoter Y/X variant, the frequency of YX
heterozygous genotype, and XX homozygous genotype was
significantly high in RVVI cases as compared to controls
and shown to be associated with increased susceptibility
to RVVI. However, MBL2 SNP L/H, P/Q, and codon 54
showed no difference in genotypic frequencies between RVVI
cases and controls (Table 3). All the studied genetic models,
except recessive, were statistically significant for MBL2 Y/X
polymorphism. Of these, the best inheritance model was found
to be dominant model with the lowest AIC/BIC-value (AIC =
611.5, BIC = 623.9) depicting that X allele carrier (either in
homozygosis or heterozygosis) had a higher risk to develop RVVI
than non-X carrier with (p < 0.0001; OR = 2.77; 95% CI =
1.87–4.09). For, P/Q polymorphism, recessive, and log additive
models were the best fit model with lowest AIC/BIC value (p
= 0.04). However, no inheritance models for L/H and codon 54
polymorphisms were found to be significant.
MBL2 Variants in Types of RVVI Cases and
Controls
To find an association betweenMBL2 polymorphisms and RVVI
types, cases previously classified into BV, VVC, and MI were
further compared for genotypic and allelic distribution with
respect to controls (Table 4). For Y/X polymorphism, X allele was
found to be significantly high in BV (p= 0.0006), VVC (p= 0.04),
andMI cases (p= 0.003) as compared to controls. Homozygosity
for X allele was significantly high in BV (p = 0.04) and MI (p =
TABLE 2 | Distribution of allelic frequencies of MBL2 polymorphisms in
RVVI cases and controls.
Alleles RVVI Cases Controls OR (95% CI) p-value
(N = 258) (N = 203)
Freq (%) Freq (%)
rs11003125
L(C) 285 (55.23) 236 (58.12) 1
H(G) 231 (44.76) 170 (41.87) 1.12 (0.86–1.46) 0.37
rs7096206
Y(G) 300 (58.13) 290 (71.4) 1
X(C) 216 (41.86) 116 (28.57) 1.8 (1.36–2.37) <0.0001*
rs7095891
P(C) 262 (50.77) 200 (49.26) 1
Q(T) 254 (49.22) 206 (50.73) 0.94 (0.72–1.22) 0.64
rs1800450
A(G) 259 (50.19) 203 (50) 1
B(A) 257 (49.80) 203 (50) 0.99 (0.76–1.28) 0.95
OR, odds ratio; CI, confidence intervals; *indicates highly significant values (P < 0.0001).
0.004) as compared to controls but not in VVC. Heterozygosity
for X allele was significantly high in BV (p < 0.0001) and VVC
(p = 0.02) comparative to controls but the difference was not
significant in MI.
For L/H, P/Q, and codon 54 polymorphisms, no significant
difference was observed either in allelic or genotypic frequency
between RVVI cases types and controls except for P/Q
polymorphism where Heterozygosity was found to be
significantly low in MI cases than controls (p = 0.007).
Also, comparison between RVVI types showed no significant
difference in MBL2 distribution (not shown in table). For P/Q
polymorphism, no homozygote for major allele in case of BV and
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TABLE 3 | Distribution of genotypic frequencies of MBL2 polymorphisms in RVVI cases and controls.
Genetic Models Genotype RVVI Cases Controls OR (95% CI) p-value AIC BIC
(N = 258) (N = 203)
Freq (%) Freq (%)
rs11003125
Codominant L/L 51 (19.8%) 52 (25.6%) 1.00
H/L 183 (70.9%) 132 (65%) 1.41 (0.90–2.21) 0.32 638.2 654.7
H/H 24 (9.3%) 19 (9.4%) 1.29 (0.63–2.63) 0.48
Dominant L/L 51 (19.8%) 52 (25.6%) 1.00 0.14 636.3 648.7
H/L-H/H 207 (80.2%) 151 (74.4%) 1.40 (0.90–2.17)
Recessive L/L-H/L 234 (90.7%) 184 (90.6%) 1.00 0.98 638.5 650.9
H/H 24 (9.3%) 19 (9.4%) 0.99 (0.53–1.87)
Overdominant L/L-H/H 75 (29.1%) 71 (35%) 1.00 0.18 636.7 649.1
H/L 183 (70.9%) 132 (65%) 1.31 (0.88–1.95)
Log-additive – – – 1.21 (0.87–1.70) 0.26 637.2 649.6
rs7096206
Codominant Y/Y 69 (26.7%) 102 (50.2%) 1
Y/X 162 (62.8%) 86 (42.4%) 2.79 (1.86–4.17) <0.0001** 613.5 630
X/X 27 (10.5%) 15 (7.4%) 2.66 (1.32–5.36) 0.001**
Dominant Y/Y 69 (26.7%) 102 (50.2%) 1
Y/X-X/X 189 (73.3%) 101 (49.8%) 2.77 (1.87–4.09) <0.0001** 611.5 623.9
Recessive Y/Y-Y/X 231 (89.5%) 188 (92.6%) 1
X/X 27 (10.5%) 15 (7.4%) 1.47 (0.76–2.83) 0.25 637.2 649.6
Overdominant Y/Y-X/X 96 (37.2%) 117 (57.6%) 1
Y/X 162 (62.8%) 86 (42.4%) 2.30 (1.58–3.35) <0.0001** 619.3 631.7
Log-additive – – – 2.06 (1.50–2.83) <0.0001** 617.1 629.5
rs7095891
Codominant P/P 5 (1.9%) 2 (1%) 1.00
P/Q 252 (97.7%) 196 (96.5%) 0.52 (0.10–2.69) 0.09 635.8 652.4
Q/Q 1 (0.4%) 5 (2.5%) 0.08 (0.01–1.19) 0.06
Dominant P/P 5 (1.9%) 2 (1%) 1
P/Q-Q/Q 253 (98.1%) 201 (99%) 0.50 (0.10–2.62) 0.4 637.8 650.2
Recessive P/P-P/Q 257 (99.6%) 198 (97.5%) 1
Q/Q 1 (0.4%) 5 (2.5%) 0.15 (0.02–1.33) 0.045* 634.5 646.9
Overdominant P/P-Q/Q 6 (2.3%) 7 (3.5%) 1
P/Q 252 (97.7%) 196 (96.5%) 1.50 (0.50–4.56) 0.47 638 650.4
Log-additive – – – 0.30 (0.08–1.10) 0.048* 634.6 647
rs1800450
Codominant A/A 1 (0.4%) 1 (0.5%) 1.00
A/B 257 (99.6%) 200 (98.5%) 1.29 (0.08–20.87) 0.19 637.2 653.7
B/B 0 (0%) 2 (1%) (NA)
Dominant A/A 1 (0.4%) 1 (0.5%) 1
A/B-B/B 257 (99.6%) 202 (99.5%) 1.27 (0.08–20.56) 0.86 638.5 650.9
Recessive A/A-A/B 258 (100%) 201 (99%) 1
B/B 0 (0%) 2 (1%) (NA) NA NA NA
Overdominant A/A-B/B 1 (0.4%) 3 (1.5%) 1
A/B 257 (99.6%) 200 (98.5%) 3.88 (0.40–37.73) 0.21 636.9 649.3
Log-additive – – – 0.33 (0.03–3.20) 0.3 637.4 649.8
Akaike’s Information Criterion (AIC) and Bayesian Information Criterion (BIC), Bold values indicate low AIC/BIC value, *indicates (p < 0.05), **indicates (p < 0.001).
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TABLE 4 | MBL2 polymorphism, distribution, and comparison of genotypes and alleles in RVVI types with control group.
No. (%) of Controls No. (%) of RVVI clinical categories Genotypic and allelic comparison
Controls (N = 203) BV (N = 97) VVC (N = 62) MI (N = 41) BV vs. Controls VVC vs. Controls MI vs. Controls
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
rs1003125
Genotypes
LL 52 (25.61) 17 (17.5) 19 (30.64) 8 (19.51) 1 1 1
LH 132 (65.02) 66 (68.04) 37 (59.6) 30 (73.17) 1.52 (0.82–2.84) 0.18 0.76 (0.40–1.45) 0.41 1.47 (0.63–3.43) 0.36
HH 19 (9.359) 14 (14.4) 6 (9.67) 3 (7.31) 2.25 (0.93–5.44) 0.07 0.86 (0.30–2.48) 0.78 1.02 (0.24–4.27) 0.97
Alleles
L 236 (58.128) 100 (51.5) 75 (60.48) 46 (56.09) 1 1 1
H 170 (41.87) 94 (48.4) 49 (39.51) 36 (43.90) 1.30 (0.92–1.84) 0.12 0.90 (0.60–1.36) 0.64 1.08 (0.67–1.75) 0.73
rs7096206
Genotypes
YY 102 (50.2) 23 (23.71) 21 (33.87) 12 (29.26) 1 1 1
YX 86 (42.3) 65 (67.01) 35 (56.45) 21 (51.21) 3.35 (1.92–5.84) <0.0001*** 1.97 (1.07–3.64) 0.02* 2.07 (0.96–4.46) 0.06
XX 15 (7.38) 9 (9.27) 6 (9.67) 8 (19.51) 2.66 (1.03–6.82) 0.04* 1.94 (0.67–5.59) 0.21 4.53 (1.59–12.90) 0.004**
Alleles
Y 290 (71.4) 111 (57.21) 77 (62.09) 45 (54.87) 1 1 1
X 116 (28.57) 83 (42.78) 47 (37.90) 37 (90.24) 1.86 (1.30–2.67) 0.0006*** 1.52 (1.00–2.32) 0.04* 2.05 (1.26–3.33) 0.003**
rs7095891
Genotypes
PP 2 (0.985) 0 1 (1.61) 4 (9.75) – NA 1 1
PQ 196 (96.55) 96 (98.96) 61 (98.38) 37 (90.24) 1 0.62 (0.05–6.98) 0.7 0.09 (0.01–0.53) 0.007**
QQ 5 (2.46) 1 (1.03) 0 0 0.40 (0.04–3.54) 0.41 – NA – NA
Alleles
P 200 (49.26) 96 (49.48) 63 (50.80) 45 (54.87) 1 1 1
Q 206 (50.73) 98 (50.51) 61 (49.19) 37 (45.12) 0.99 (0.70–1.39) 0.95 0.94 (0.62–1.40) 0.76 0.79 (0.49–1.28) 0.35
rs1800450
Genotypes
AA 1 (0.49) 1 (1.03) 0 (0) 0 (0) – NA – NA – NA
AB 200 (98.52) 96 (98.9) 62 (100) 41 (100) – NA – NA – NA
BB 2 (0.98) 0 (0) 0 (0) 0 (0) – NA – NA – NA
Alleles
A 202 (49.75) 98 (50.5) 62 (50) 41 (50) 1 1 1
B 204 (50.24) 96 (49.4) 62 (50) 41 (50) 0.97 (0.68–1.36) 0.86 0.99 (0.66–1.48) 0.96 0.99 (0.61–1.59) 0.96
OR, Odds Ratio; CI, Confidence Intervals, *indicates significant p-values (p < 0.05), **indicates high significant values (p < 0.01), ***indicates highly significant values (p < 0.001).
for minor allele in case of VVC and MI was observed. For codon
54 polymorphism, only one homozygote of wild allele A in case
of BV was observed whereas no homozygote was observed in
VVC and MI.
Linkage disequilibrium and Haplotypes
The Linkage disequilibrium (LD) between studied SNPs
indicated strong LD between codon 54 and P/Q variant
(Figure 1). While others SNPs i.e., codon 54 and P/Q variants
were found to be in fairly high LDwith L/H and Y/X variants. The
MBL2 secretor haplotypes distributions and their comparison
among cases-control groups were observed (Table 5). There were
significant difference (global p = 0.01) in haplotype frequency
between cases and controls. Apart from well-known MBL2
secretor haplotypes, present study have also observed nine
additional MBL2 haplotypes, of which HXPA, LYQB, HYQB,
LXQB, and HXQB, were observed with frequency ≥ 0.05.
Independent analysis of each individual haplotypes indicated that
haplotype LYQB was found to be significantly low in total RVVI
cases (p = 0.006), BV cases (p < 0.0001), and MI cases (p =
0.05) than controls. Haplotypes, HXPA was significantly higher
in RVVI cases (p = 0.05) and MI cases (P = 0.04) than controls
and LXQB was significantly higher in RVVI cases (p = 0.04)
than controls. However, no other difference was observed in
haplotypes distribution.
sMBL Levels in RVVI Cases and Healthy
Controls
Tukey’s test revealed that RVVI cases and its subtypes BV, VVC,
and MI showed significantly low level of sMBL as compared
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FIGURE 1 | LD pattern ofMBL2 variants in all subjects. Numbers indicate
the D′-value expressed as percentile.
to controls (Figure 2). Also, significantly low sMBL levels were
observed in VVC cases as compared to RVVI and MI at p< 0.05
(Figure 2).
Genotype-Phenotype Association of MBL
Polymorphisms
The sMBL levels were segregated based on genotypes of different
MBL2 polymorphisms studied in the different cases groups
and controls (Figures 3A–D). Data analysis by Tukey’s test for
genotypic sMBL levels in one particular SNP indicated that,
within controls, variant QQ genotype contributed significantly
low sMBL levels than PQ genotype. Similarly, sMBL levels for
L/H polymorphism when compared within cases revealed that,
in RVVI cases, LH genotype contribute significantly high sMBL
levels than LL and HH genotypes while in BV cases significant
difference was found between LL and LH genotypes only.
Comparison of genotypic sMBL levels of cases with respective
controls by Student’s t-test showed, significantly low sMBL levels
in various L/H genotypes of RVVI, BV, and VVC cases as
compared to respective control genotypes. However, in MI cases,
only significant difference was observed between sMBL levels of
homozygous variant genotype HH with respective genotype of
control. For Y/X polymorphism, overall significant low sMBL
levels were observed in various Y/X genotypes in RVVI, BV,
and VVC cases as compared to respective genotypes of controls.
For P/Q polymorphism, only significant difference was found in
heterozygous PQ genotype of RVVI and its types with respective
controls genotype. For A/B polymorphism, significant low sMBL
levels of AB genotype were observed in RVVI and its types as
compared to AB genotype of controls.
Haplotypes and sMBL Levels
Mean sMBL levels of Individual haplotypes in cases and control
groups were also studied (Figures 4A–D). In controls, HXPA
haplotype was contributing significant low levels than LXPA
and LYQB haplotypes while no difference was observed among
sMBL of other haplotypes within control. In RVVI cases, LYPA
and LXPA haplotypes were contributing significant low levels
than HYPA and LYQB haplotypes, while no differences were
observed in sMBL of other haplotypes within RVVI cases. Also,
all the RVVI haplotypes except HXPA haplotype were found
to be contributing significant low levels than their respective
haplotype in controls. In BV cases, LYPA, LXPA, and HXPA
haplotypes were contributing significant low levels than LYQB
haplotype. All the haplotypes in BV except HXPA haplotype
contributed significantly low levels than respective haplotypes in
controls. InVVC cases, LYPA, LXPA, and HXPA haplotypes were
contributing significant low levels than HYPA, LYQB, andHXQB
haplotypes. Significant difference was observed between all the
haplotypes of VVC cases with respective controls haplotypes.
In MI cases, haplotypes HYPA, HXPA, LYPA, and LXQB
were contributing significantly low level than LYQB. However,
significant difference was observed for HYPA, LYPA, and LXQB
haplotypes of MI cases with respective haplotypes of controls.
DISCUSSION
Majority of the microorganism induced responses are triggered
by a set of germ line encoded PRRs that recognize Pathogen
Associated Molecular Patterns (PAMPs) present on microbial
pathogen surfaces (Mogensen, 2009; Kumar et al., 2011; Santoni
et al., 2015). Genetic changes in these PRRs are suggested as a
contributing factor for disease development (Mogensen, 2009).
MBL is one such multi functioning PRR that is involved in fine
tuning the immune system. Our earlier report, based on in silico
analysis filtered out, 12 functionally important SNPs of MBL2
gene (Kalia et al., 2016). Out of these, four SNPs i.e., H/L, Y/X,
and P/Q and codon 54 of MBL2 are widely studied and found
to be associated with different diseases. However, no studies to
date have investigated the role of these variants along with its
serum levels in RVVI and its types making the present study first
approach toward it.
The best fit model for Y/X polymorphism depicted X allele as
a dominant allele. Homozygosity and heterozygosity of X allele
was found at significantly higher frequencies in RVVI cases and
its types which increases the risk for developing RVVI, BV, VVC,
and MI. Concluding that one leading mechanism responsible for
RVVI and its types in women is MBL Y/X polymorphism. No
study, to our knowledge has evaluated the role ofMBL2 promoter
polymorphism in association with RVVI and its types. However,
these promoter variants have been associated in susceptibility
toward various diseases (Meyrowitsch et al., 2010; Martiny et al.,
2011; Singla et al., 2012; Weitzel et al., 2012; Li et al., 2013; Panda
et al., 2013; Chen et al., 2014; Jha et al., 2014; Das and Panda,
2015).
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FIGURE 2 | Serum MBL levels in different clinical categories of RVVI
and healthy controls (HC). Data are mean ± standard error, One-way
ANOVA and Tukey’s HSD. Means that do not share the same superscript are
significantly different from each other at P < 0.05.
No significant difference was found for MBL codon 54
polymorphism in RVVI cases and its types. This finding is in
agreement with two studies demonstrating, lack of association
between functional polymorphisms in the first exon of MBL2
with VVC and recurrent BV (De Seta et al., 2007; Milanese
et al., 2008). Also no homozygous genotype (BB) of codon 54
polymorphism was observed in RVVI cases and its types and this
finding of the present study was in accordance with a previous
study, where no BB genotype was observed in VVC cases (Liu
et al., 2006). However, the results of the present study were
contrary to some other studies where codon 54 polymorphism
was found to be associated with increased risk of VVC and BV
(Babula et al., 2003; Liu et al., 2006; Giraldo et al., 2007; Donders
et al., 2008; Wojitani et al., 2012). These differences in genetic
susceptibility can be attributed to genetic heterogeneity between
different ethnicities and thus indicated the need, to evaluate these
polymorphisms in different populations.
Of the seven commonly known haplotypes reported
previously, only five haplotypes were observed in the present
study (Madsen et al., 1995, 1998; Turner, 2003; Lee et al.,
2005). The other two haplotypes HYPD and LYQC were not
observed because codon 52 and 57 polymorphisms were not
taken into consideration due to their low minor allele frequency.
In addition to these well-known haplotypes, present study has
also observed nine additionalMBL2 haplotypes, of which HXPA,
LYQB, HYQB, LXQB, and HXQB, were observed with frequency
≥ 0.05. Out of these nine haplotypes, four haplotypes i.e., HXPA,
LYQB, HYQA, LXPB were also reported previously (Verdu et al.,
2006; Oudshoorn et al., 2008; Jha et al., 2014). The rest of five
haplotypes are novel and reported for the first time in this study.
These novel haplotypes were categorized into high and low
secretor haplotypes based on the previous literature stating the
association of wild allele of Y/X and A/B SNPs with high basal
expression and variant alleles with low basal expression and
hence circulating sMBL levels (Sumiya et al., 1991; Lipscombe
et al., 1992; Madsen et al., 1994, 1995; Terai et al., 2003; Larsen
et al., 2004; Garred et al., 2006; Antony et al., 2013; Jha et al.,
2014; Das and Panda, 2015; Mashaly et al., 2016).
Stratification based on MBL2 haplotypes has shown
significantly high prevalence of HXPA haplotype in RVVI
and MI cases, whereas, LXQB haplotype was significantly
more common in RVVI cases. Thus, indicating X allele as an
important marker providing risk toward RVVI. On the other
hand, LYQB a low secretor haplotype provided significant
protection against RVVI (OR; 0.58), BV (OR; 0.27), and MI
cases (OR; 0.62) with high frequency observed in controls.
However, the same haplotype was reported with a very low
frequency (1%) in case of severe malaria in Indian population
with no LYQB haplotype in control (Jha et al., 2014). Overall
high prevalence of low secretor haplotypes were observed in
both cases and controls of the present study. In agreement to
these findings, the high prevalence of high secretor haplotype
LYPA in cases and low secretor haplotype HYPD in controls
was also reported previously in Brazilian population in Leprosy
(de Messias-Reason et al., 2007). The high prevalence of low
secretor MBL2 haplotypes in different populations, including
LYQC in Africans and LYPB in South American Amerindians
was also documented (Boldt et al., 2006a,b). Taken together, the
data suggests that sturdy forces have exerted positive selective
pressure on these haplotypes across the globe.
Significantly low sMBL levels were observed in RVVI cases
and its various categories as compared to controls, indicating
MBL insufficiency as a possible risk factor for the rapid
progression of RVVI. Similar to the situation of the present study,
two studies have reported lowMBL levels in cervicovaginal fluids
of RVVC cases than controls (Babula et al., 2003; Liu et al., 2006).
However, serumMBL analysis was preferred in the present study
as vaginal secretion are reported to differs in MBL composition
throughout the menstrual cycle as it derives both from plasma as
well as from local synthesis. Furthermore, MBL level in vaginal
secretions is also documented to be progesterone dependent
(Bulla et al., 2010; Henic´ et al., 2010). The finding of the present
study are contradictory to a study in Italian white Caucasian
population where no significant difference was foundwhen sMBL
levels were compared between VVC, BV, and controls (Milanese
et al., 2008) and to the study where significantly higher sMBL
levels were found in women suffering from RVVC than in
healthy women (Henic´ et al., 2010). Among various categories
of RVVI cases, VVC cases showed significantly low sMBL levels
as compared to BV and MI cases of the present study. MBL was
shown to bind with diverse Candida species, inhibits growth and
provides defense against fungal infections like VVC (Neth et al.,
2000; Ip and Lau, 2004; Pellis et al., 2005; Moslem et al., 2015;
Sobel, 2016). Hence, decreased sMBL levels observed in VVC
cases of the present study reflects failure of defense mechanism
and increased susceptibility in these cases. In addition to this,
many of the bacteria and other pathogens have also been shown
to be recognized byMBL (Neth et al., 2000; Townsend et al., 2001;
Hamvas et al., 2005).
The present study also revealed an association of MBL
polymorphism with its serum levels. It was found that for the
same genotypes, MBL levels of cases were significantly low than
respective control genotypes. As expected, sMBL concentration
for A/B polymorphism in this study varied according to the
individual’s MBL genotypes with highest sMBL levels in wild
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FIGURE 3 | Distribution of sMBL levels in different MBL2 genotypes. Serum MBL levels (mean ± standard error) according to different genotypes of studied
MBL2 variants in RVVI with controls (A) and RVVI types with controls that includes BV (B), VVC (C), and MI (D). Asterisks represents comparison of cases with
respective controls by Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). Letters denote Tukey’s multiple comparison test. Upper case letters denote Tukey’s test
within controls of one particular SNP, Lower cases letter denote Tukey’s test within cases of one particular SNP. Means that do not share the same superscript are
significantly different from each other at p < 0.05. Bars with no letters are not included in statistical analysis due to their low frequency of genotype observed in
population.
genotype, and lowest in variant genotype (Madsen et al., 1995;
Steffensen et al., 2000; Minchinton et al., 2002). This finding was
in accordance with the study in Italian white Caucasian cases
with recurrent vaginal infections (Milanese et al., 2008). Similar
situation was also observed in cervicovaginal fluids of Latvian
cases with recurrent VVC (Babula et al., 2003).
The sMBL levels were also studied in relation to high and
low secretor haplotypes. Overall it was found that for the same
haplotypes, sMBL levels of cases were contributing significantly
low levels than control. However, when haplotypes were observed
within cases and controls, it was found that LYPA “high secretor
haplotype” was contributing significantly low MBL levels than
LYQB “low secretor haplotype” in all cases types and control.
Also, low secretor haplotype LXPA was contributing high sMBL
levels in controls population while same haplotype LXPA was
contributing low sMBL levels in cases. Similar results was also
reported previously, where HYPA high secretor haplotype were
significantly contributing low sMBL in the South American
Indians than in other populations (e.g., the Eskimos; Madsen
et al., 1998). These findings suggest the presence of some
other down-regulating variants that exist outside the region of
haplotype observed which cannot be omitted.
However, in the present study, allelic and genotypic
frequencies of MBL polymorphisms deviated from HWE except
that of control population in case of Y/X polymorphism
(χ2 = 0.292; p = 0.589). Disagreement of genotypes distribution
from HWE has been attributed to population stratifications
or selection pressure (Hosking et al., 2004). Reason could be
Infectious diseases or involvement of subjects from similar
geographical area due to hospital based study (Miller, 1999;
Ghosh, 2008; Fumagalli et al., 2009).
CONCLUSIONS AND FUTURE
DIRECTIONS
The findings of the present study suggested low sMBL levels
and X allele as contributing risk factors toward development
of RVVI. Fortuitously, infusion therapy of recombinant MBL
is indicated to be safe in MBL-deficient subjects (Valdimarsson
et al., 1998; Garred et al., 2002). Thus, women with RVVI
can be tested for the above-mentioned associations and might
be benefitted from MBL replacement therapy. The genotype-
phenotype relationship observed in the present study suggests
RVVI and its types as multifactorial phenotypes, possibly
implicating the combined effect of several host genes involved
in innate immunity. Furthermore, the findings of this study also
suggest the positive selection pressure exerted by RVVI, leading
to increased frequency of novel low secretor haplotypes. Thus,
further investigations involving detection of pathogen specific
antibodies levels, MBL2 expression analysis etc. are required
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FIGURE 4 | Distribution of MBL levels in different MBL2 Haplotypes. Serum MBL levels (mean ± standard error) according to different haplotypes of studied
MBL2 variants in RVVI with controls (A) and RVVI types with controls that includes BV (B), VVC (C), and MI (D). Asterisks represents comparison of cases with
respective controls by Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). Letters denote Tukey’s multiple comparison test. Upper case letters denote Tukey’s test
within controls, lower cases letter denote Tukey’s test within cases. Means that do not share the same superscript are significantly different from each other at p <
0.05.
to fully reveal the genetic, immunologic, and environmental
variables that influence a woman’s likelihood to develop RVVI.
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